Inventiva (IVA) Competitors $5.47 +0.51 (+10.28%) Closing price 04:00 PM EasternExtended Trading$5.42 -0.04 (-0.82%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVA vs. BHC, IDYA, BLTE, IBRX, ARQT, RXRX, MESO, IRON, AGIO, and DNLIShould you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include Bausch Health Cos (BHC), IDEAYA Biosciences (IDYA), Belite Bio (BLTE), ImmunityBio (IBRX), Arcutis Biotherapeutics (ARQT), Recursion Pharmaceuticals (RXRX), Mesoblast (MESO), Disc Medicine (IRON), Agios Pharmaceuticals (AGIO), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. Inventiva vs. Its Competitors Bausch Health Cos IDEAYA Biosciences Belite Bio ImmunityBio Arcutis Biotherapeutics Recursion Pharmaceuticals Mesoblast Disc Medicine Agios Pharmaceuticals Denali Therapeutics Inventiva (NASDAQ:IVA) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings. Is IVA or BHC more profitable? Bausch Health Cos has a net margin of 0.99% compared to Inventiva's net margin of 0.00%. Inventiva's return on equity of 0.00% beat Bausch Health Cos' return on equity.Company Net Margins Return on Equity Return on Assets InventivaN/A N/A N/A Bausch Health Cos 0.99%-852.36%5.25% Do analysts prefer IVA or BHC? Inventiva presently has a consensus price target of $16.14, indicating a potential upside of 195.12%. Bausch Health Cos has a consensus price target of $9.00, indicating a potential upside of 49.13%. Given Inventiva's stronger consensus rating and higher probable upside, research analysts plainly believe Inventiva is more favorable than Bausch Health Cos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inventiva 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63Bausch Health Cos 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility & risk, IVA or BHC? Inventiva has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Bausch Health Cos has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Which has stronger earnings & valuation, IVA or BHC? Bausch Health Cos has higher revenue and earnings than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInventiva$9.95M52.59-$199.34MN/AN/ABausch Health Cos$9.63B0.23-$46M$0.2623.21 Does the media prefer IVA or BHC? In the previous week, Inventiva had 16 more articles in the media than Bausch Health Cos. MarketBeat recorded 19 mentions for Inventiva and 3 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.25 beat Inventiva's score of 0.09 indicating that Bausch Health Cos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 2 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bausch Health Cos 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders have more ownership in IVA or BHC? 19.1% of Inventiva shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 20.0% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryInventiva beats Bausch Health Cos on 8 of the 14 factors compared between the two stocks. Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVA vs. The Competition Export to ExcelMetricInventivaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$523.26M$3.40B$6.05B$10.51BDividend YieldN/A2.30%5.73%4.80%P/E RatioN/A22.9285.4427.36Price / Sales52.59270.00515.26195.91Price / CashN/A46.9537.5761.53Price / Book-4.5210.5512.426.82Net Income-$199.34M-$52.58M$3.32B$276.89M7 Day Performance2.05%1.09%1.01%0.27%1 Month Performance3.01%16.09%10.75%8.31%1 Year Performance112.02%18.41%76.20%35.60% Inventiva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVAInventiva3.2233 of 5 stars$5.47+10.3%$16.14+195.1%+85.8%$474.48M$9.95M0.00100Analyst RevisionGap DownHigh Trading VolumeBHCBausch Health Cos4.4901 of 5 stars$6.48-3.0%$9.00+38.9%-25.7%$2.47B$9.86B24.9220,700IDYAIDEAYA Biosciences4.0128 of 5 stars$27.49-0.5%$43.36+57.7%-11.2%$2.42B$7M-7.2580BLTEBelite Bio2.4441 of 5 stars$78.10+3.3%$96.00+22.9%+42.0%$2.41BN/A-50.3910IBRXImmunityBio2.5613 of 5 stars$2.53-0.4%$10.75+324.9%-32.5%$2.40B$14.74M-5.27590Analyst ForecastARQTArcutis Biotherapeutics1.3931 of 5 stars$19.76-0.8%$19.80+0.2%+109.8%$2.39B$196.54M-26.35150Analyst ForecastRXRXRecursion Pharmaceuticals1.2048 of 5 stars$5.53+0.7%$7.25+31.1%-12.4%$2.38B$58.84M-3.11400Gap UpMESOMesoblast1.9124 of 5 stars$17.32-5.9%$24.00+38.6%+79.2%$2.36B$17.20M0.0080IRONDisc Medicine2.4195 of 5 stars$69.28+2.2%$98.30+41.9%+52.1%$2.36BN/A-15.5030AGIOAgios Pharmaceuticals4.4864 of 5 stars$40.89+1.0%$56.00+37.0%-2.5%$2.35B$36.50M3.72390DNLIDenali Therapeutics4.3236 of 5 stars$15.22-1.3%$33.50+120.1%-43.3%$2.25BN/A-5.44430News Coverage Related Companies and Tools Related Companies BHC Competitors IDYA Competitors BLTE Competitors IBRX Competitors ARQT Competitors RXRX Competitors MESO Competitors IRON Competitors AGIO Competitors DNLI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IVA) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
